Back HIV/HCV Coinfection

HIV/HCV Coinfection

Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.

HIVandHepatitis.com coverage by topic

CROI website

4/16/17

alt

CROI 2017: Higher than Expected HCV Prevalence Among HIV- Gay Men in Amsterdam PrEP Program

An unexpectedly high number of HIV-negative gay and bisexual men taking pre-exposure prophylaxis (PrEP) in Amsterdam were found to have hepatitis C virus (HCV) infection, suggesting HCV is being transmitted sexually between men with and without HIV, according to a presentation last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.

alt

Read more:

AIDS 2016: AbbVie 3D and 2D Hepatitis C Combos Work Well for HIV/HCV Coinfected People

AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well-tolerated for HIV-positive people with HCV coinfection in the TURQUOISE-I trial, according to a report at the 21st International AIDS Conference last week in Durban.

alt

Read more:

CROI 2017: DAA Therapy Cures HIV/HCV Coinfected People with Decompensated Cirrhosis or Transplants

HIV/HCV coinfected people with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for hepatitis C, according to 3 Spanish studies presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle.

alt

Read more:

Coverage of 21st International AIDS Conference (AIDS 2016)

HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.

Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.

Full listing by topic

AIDS 2016 website

7/28/16

alt

CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

Read more:

AIDS 2016: Sofosbuvir/ Velpatasvir Shows High Cure Rate in HIV/HCV Coinfection Study

The once-daily coformulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes and was safe and well tolerated by HIV/HCV coinfected patients in the ASTRAL-5 trial, according to results presented at the 21st International AIDS Conference (AIDS 2016)this week in Durban. A related analysis showed that sofosbuvir/velpatasvir can be safely combined with most widely used antiretrovirals, with the exception of efavirenz.

alt

Read more:

CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands

A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle. 

alt

Read more:

Incidence of Liver Cancer Is Increasing Among People with HIV/HCV Coinfection

Incidence of liver cancer is increasing among people with HIV co-infection, an international team of investigators report in the June 15 online edition of Clinical Infectious Diseases. Researchers from Europe and Canada pooled data gathered between 2001 and 2014 from 6 prospective cohorts and found that incidence of hepatocellular carcinoma (HCC) increased, but the incidence of serious liver related events -- decompensated liver disease or liver-related death -- declined.

alt

Read more:

CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?

HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

Read more:

EASL 2016: Does Having HIV Affect Response to Hepatitis C Treatment?

A study from the U.S. Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that HIV/HCV coinfected people were less likely to be cured. These conflicting findings, presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona, indicate that the interactions between HIV and hepatitis C are still not fully understood.alt

Read more:

AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts

The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver Meeting this month in Boston.

alt

Read more:

EASL 2016: Sofosbuvir/ Velpatasvir Cures 95% of HIV/HCV Coinfected People

A dual regimen of sofosbuvir plus velpatasvir was well-tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C coinfection, according to results from the Phase 3 ASTRAL-5 trial presented at the 2016 EASL International Liver Congress last week in Barcelona.

alt

Read more:

AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid

More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C -- including many with liver cirrhosis -- achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce results as good as those seen in formal clinical trials, according to results from a Spanish study presented at the AASLD Liver Meeting this month in Boston.

alt

Read more:

CROI 2016: Hepatitis C [VIDEO]

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

 

Read more:

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full listing by topic

Liver Meeting 2016 website

11/20/16

alt

CROI 2016: Advances in Hepatitis C Research [VIDEO]

Interferon-free therapy can now cure most patients with chronic hepatitis C, but challenges still remain, including persistent liver damage and cancer risk and HCV reinfection after successful treatment. A panel of hepatitis C experts discuss research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) and related news with HIVandHepatitis.com editor Liz Highleyman in this IFARA video update.

alt

 

Read more:

Coverage of IDWeek 2016

HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.

Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.

Full listing of coverage by topic

IDWeek website

11/4/16

alt

 

More Than 2 Million People Worldwide Are Coinfected with HIV and Hepatitis C

Approximately 2.3 million people are living with both HIV and hepatitis C virus (HCV), about half of whom are people who inject drugs, according to a meta-analysis of nearly 800 studies published in the February 24 advance online edition of The Lancet. The analysis found that the overall likelihood of people with HIV being coinfected with HCV is about 6%, but good data are lacking for many countries.

alt

Read more:

Improved HIV Treatment Has Not Reduced End-Stage Liver Disease in HIV/HCV Coinfected People

Incidence of end-stage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the U.S. report in the November 1 edition of Clinical Infectious Diseases

alt

Read more:

CROI 2016: Sofosbuvir/ Velpatasvir for Hepatitis C Can Be Administered with Most Antiretrovirals

Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last week in Boston.

alt

Read more: